These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 1413197)

  • 41. [Hallucinogen-induced psychological disorders].
    Hermle L; Kovar KA; Hewer W; Ruchsow M
    Fortschr Neurol Psychiatr; 2008 Jun; 76(6):334-42. PubMed ID: 18512184
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunochemical monitoring of psilocybin and psilocin to identify hallucinogenic mushrooms.
    Morita I; Oyama H; Kiguchi Y; Oguri A; Fujimoto N; Takeuchi A; Tanaka R; Ogata J; Kikura-Hanajiri R; Kobayashi N
    J Pharm Biomed Anal; 2020 Oct; 190():113485. PubMed ID: 32866746
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dependence on LSD and other hallucinogenic drugs.
    JAMA; 1967 Oct; 202(1):141-4. PubMed ID: 6072003
    [No Abstract]   [Full Text] [Related]  

  • 44. Abuse of indigenous psilocybin mushrooms: a new fashion and some psychiatric complications.
    Hyde C; Glancy G; Omerod P; Hall D; Taylor GS
    Br J Psychiatry; 1978 Jun; 132():602-4. PubMed ID: 566144
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Unpredictable Behavior Under the Influence of "Magic Mushrooms": A Case Report and Review of the Literature.
    Honyiglo E; Franchi A; Cartiser N; Bottinelli C; Advenier AS; Bévalot F; Fanton L
    J Forensic Sci; 2019 Jul; 64(4):1266-1270. PubMed ID: 30548541
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [The toxicological aspects of poisonings by psilocybine-containing mushrooms].
    Babakhanian RV; Bushuev ES; Kazankov SP; Kostyrko TA
    Sud Med Ekspert; 1997; 40(3):20-2. PubMed ID: 9304247
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The rising price of mushrooms.
    Young RE; Milroy R; Hutchison S; Kesson CM
    Lancet; 1982 Jan; 1(8265):213-5. PubMed ID: 6119567
    [No Abstract]   [Full Text] [Related]  

  • 48. Harm potential of magic mushroom use: a review.
    van Amsterdam J; Opperhuizen A; van den Brink W
    Regul Toxicol Pharmacol; 2011 Apr; 59(3):423-9. PubMed ID: 21256914
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Liberty caps: recreational hallucinogenic mushrooms.
    Pollock SH
    Drug Alcohol Depend; 1976 Oct; 1(6):445-7. PubMed ID: 1035156
    [No Abstract]   [Full Text] [Related]  

  • 50. Peak experiences of psilocybin users and non-users.
    Cummins C; Lyke J
    J Psychoactive Drugs; 2013; 45(2):189-94. PubMed ID: 23909006
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hallucinogen Use Disorders.
    Hardaway R; Schweitzer J; Suzuki J
    Child Adolesc Psychiatr Clin N Am; 2016 Jul; 25(3):489-96. PubMed ID: 27338969
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [A caution for psilocybine in wild mushrooms. A young addict acquired acute delirium].
    Bergman B; Karlsson AC
    Lakartidningen; 1995 Oct; 92(41):3779-80. PubMed ID: 7564628
    [No Abstract]   [Full Text] [Related]  

  • 53. [Emergent drugs (III): hallucinogenic plants and mushrooms].
    Burillo-Putze G; López Briz E; Climent Díaz B; Munné Mas P; Nogue Xarau S; Pinillos MA; Hoffman RS
    An Sist Sanit Navar; 2013; 36(3):505-18. PubMed ID: 24406363
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin.
    Barrett FS; Johnson MW; Griffiths RR
    J Psychopharmacol; 2015 Nov; 29(11):1182-90. PubMed ID: 26442957
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Severe rhabdomyolysis, acute renal failure and posterior encephalopathy after 'magic mushroom' abuse.
    Bickel M; Ditting T; Watz H; Roesler A; Weidauer S; Jacobi V; Gueller S; Betz C; Fichtlscherer S; Stein J
    Eur J Emerg Med; 2005 Dec; 12(6):306-8. PubMed ID: 16276262
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms.
    Kopra EI; Ferris JA; Winstock AR; Young AH; Rucker JJ
    J Psychopharmacol; 2022 Aug; 36(8):965-973. PubMed ID: 35388724
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Increased intensity of Ecstasy and polydrug usage in the more experienced recreational Ecstasy/MDMA users: a WWW study.
    Scholey AB; Parrott AC; Buchanan T; Heffernan TM; Ling J; Rodgers J
    Addict Behav; 2004 Jun; 29(4):743-52. PubMed ID: 15135556
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The evaluation of methods of usage of addictive substances among high school students and Gdańsk University students].
    Chodorowski Z; Sein Anand J; Sein Anand I; Salamon M
    Przegl Lek; 2000; 57(10):549-52. PubMed ID: 11199884
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Increasing use of "Ecstasy" (MDMA) and other hallucinogens on a college campus.
    Cuomo MJ; Dyment PG; Gammino VM
    J Am Coll Health; 1994 May; 42(6):271-4. PubMed ID: 7913938
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Psychoactive drugs and quality of life.
    Ventegodt S; Merrick J
    ScientificWorldJournal; 2003 Aug; 3():694-706. PubMed ID: 12941969
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.